Gossamer Bio (GOSS) vs RenovoRx (RNXT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
RenovoRx (RNXT) has outperformed Gossamer Bio (GOSS) over the past year, gaining 9.9% versus a loss of 94.9%. Over five years, RNXT leads with a -77.8% price change compared with -99.1% for GOSS. RenovoRx is the larger company by market cap ($57.8 million vs $56.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GOSS | RNXT |
|---|---|---|
| Share price | $9.31 | $1.28 |
| Market cap | $56.94M | $57.77M |
| 1-day change | -5.77% | -3.76% |
| YTD return | -96.02% | +58.33% |
| 1-year return | -94.90% | +9.92% |
| 5-year return | -99.12% | -77.76% |
| EPS (TTM) | $-52.80 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $309.60 | $2.59 |
| 52-week low | $9.12 | $0.701 |
| Distance from 52-week high | -96.99% | -50.58% |
| Analyst consensus | buy | none |
| Avg. price target upside | +785.93% | +457.03% |
| Average volume | 378.37K | 765.87K |
| Shares outstanding | 6.12M | 45.13M |
| Employees | 161 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNXT has outperformed GOSS by 104.8 percentage points over the past year.
About Gossamer Bio
GOSS stock →Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
About RenovoRx
RNXT stock →RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
GOSS vs RNXT FAQ
Which is bigger, Gossamer Bio or RenovoRx?
RenovoRx (RNXT) is larger, with a market capitalization of $57.77M compared with $56.94M for Gossamer Bio (GOSS).
Which stock has performed better over the past year, GOSS or RNXT?
RNXT returned +9.92% over the past 12 months, compared with -94.90% for GOSS (price return, excluding dividends). Past performance does not predict future results.
Are Gossamer Bio and RenovoRx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.